ArticleMolecular & cellular proteomics : MCP2011
Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries.
Article in Molecular & cellular proteomics : MCP, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.PloS one · 2017Pooled it
- Antibody array-based proteome approach reveals proteins involved in grape seed development.Plant physiology · 2024Article
- Cross-Sectional and Longitudinal Associations of Serum LRG1 with Severity and Prognosis Among Adult Community-Acquired Pneumonia Patients.Journal of inflammation research · 2024Article
- Large-Scale Plasma Proteome Epitome Profiling is an Efficient Tool for the Discovery of Cancer Biomarkers.Molecular & cellular proteomics : MCP · 2023Article
- Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.Cancer research communications · 2023Article
- LRG1: an emerging player in disease pathogenesis.Journal of biomedical science · 2022Review
- Detection of leucine-rich alpha-2-glycoprotein 1 containing immunocomplexes in the plasma of lung cancer patients with epitope-specific mAbs.Cancer biomarkers : section A of Disease markers · 2022Article
- Advances in the application of proteomics in lung cancer.Frontiers in oncology · 2022Review
- Proteomics of Non-human Primate Plasma after Partial-body Radiation with Minimal Bone Marrow Sparing.Health physics · 2020Article
- Article
- Application of an antibody chip for screening differentially expressed proteins during peach ripening and identification of a metabolon in the SAM cycle to generate a peach ethylene biosynthesis model.Horticulture research · 2020Article
- Clinical Significance ofCancers · 2019Article
- Idiotypic and anti-idiotypic antibodies against polycyclic aromatic hydrocarbon in human blood serum are new biomarkers of lung cancer.Oncotarget · 2019Article
- Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model.Journal of toxicologic pathology · 2019Article
- Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach.PloS one · 2019Article
- Comparative proteomic analysis in serum of former uranium miners with and without radon induced squamous lung cancer.Journal of occupational medicine and toxicology (London, England) · 2019Article
- Metabolome-based biomarkers: their potential role in the early detection of lung cancer.Contemporary oncology (Poznan, Poland) · 2018Review
- Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics.PloS one · 2018Article
- Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.Journal of the National Cancer Institute · 2017Article
- LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells.Journal of translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
A challenge in the treatment of lung cancer is the lack of early diagnostics. Here, we describe the application of monoclonal antibody proteomics for discovery of a panel of biomarkers for early detection (stage I) of non-small cell lung cancer (NSCLC). We produced large monoclonal antibody libraries directed against the natural form of protein antigens present in the plasma of NSCLC patients. Plasma biomarkers associated with the presence of lung cancer were detected via high throughput ELISA. Differential profiling of plasma proteomes of four clinical cohorts, totaling 301 patients with lung cancer and 235 healthy controls, identified 13 lung cancer-associated (p < 0.05) monoclonal antibodies. The monoclonal antibodies recognize five different cognate proteins identified using immunoprecipitation followed by mass spectrometry. Four of the five antigens were present in non-small cell lung cancer cells in situ. The approach is capable of generating independent antibodies against different epitopes of the same proteins, allowing fast translation to multiplexed sandwich assays. Based on these results, we have verified in two independent clinical collections a panel of five biomarkers for classifying patient disease status with a diagnostics performance of 77% sensitivity and 87% specificity. Combining CYFRA, an established cancer marker, with the panel resulted in a performance of 83% sensitivity at 95% specificity for stage I NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.